Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and ...

Coherus Oncology, Inc. is rated a Buy driven by a promising clinical pipeline and undervaluation. Learn more about CHRS stock ...

A parliamentary panel urged India to create a single, independent Ayush drug regulator. It called for unified standards, better ADR reporting, and a digital CTMS to ensure safety and global trust.

In a new observational study published in Cancer, commonly prescribed chronic medications did not affect the efficacy of ...

Healthcare information technology (IT) continues to garner substantial investor attention in 2025 as digital transformation ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...

Often undiagnosed, only about one-third of fibroids are large enough to be detected during a physical examination ...

Objective Chronic kidney disease (CKD) arises due to uncontrolled hypertension (HTN). HTN significantly increases the risk of complications in vital organs, mainly the kidneys. If hypertensive ...

M42 is committed to the sustainable future of global health – from Abu Dhabi to the world. The company’s strategy involves ...

Is now the time for gold explorers? The price of gold remains firmly above USD 4,300 per ounce, and shares of gold producers are performing well, perhaps even a little too well. Investors looking to ...

Artificial intelligence (AI) is poised to transform nuclear medicine along multiple, interconnected directions. On the translational side, AI can accelerate ...